Wells Fargo analyst Tiago Fauth initiated coverage of Alnylam with an Equal Weight rating and $171 price target. The firm contends that the risk/reward heading into into HELIOS-B Phase 3 study of vutrisiran “looks balanced”.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALNY: